-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10

Benzinga·08/17/2026 12:21:15
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.